LILLY'S JAYPIRCA (PIRTOBRUTINIB) MET ITS PRIMARY ENDPOINT IN FIRST-OF-ITS-KIND, HEAD-TO-HEAD PHASE 3 STUDY VERSUS IMBRUVICA (IBRUTINIB)

Reuters · 1d ago

Please log in to view news